https://www.selleckchem.com/pr....oducts/tyloxapol.htm
ction (4.3/24 points on the IES-6). At the end of the programme the data showed that 17% reduced opioid medication and 25% stopped all opioid use. Conclusions Veterans made clinically and statistically significant improvements, including those with co-existing PTSD, who also reduced their symptom level. This serves to demonstrate the feasibility of treating veterans with both chronic pain and PTSD using a PMP model of care. Implications Military veterans experiencing both chronic pain and PTSD can be treated in a PMP adapted for their
Curtir
Comentario
Compartilhar
